Shanghai Zerun Biotechnology

Company snapshot

Shanghai Zerun Biotechnology is a pharma organization headquartered in Shanghai, CN. Primary therapeutic focus areas include Idiopathic Pulmonary Fibrosis, Prevention of breast cancer in women with a BRCA1 germline mutation, endocrine-responsive HER2-negative early breast cancer, Breast cancer, Endometriosis. NovaPharmaNews links 11 clinical program(s), 0 drug profile(s), and 11 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 2 (5), phase 3 (3), phase 1 (2).

• 11 active pipeline program(s) linked via ClinicalTrials.gov.
• 11 US patent(s) indexed to this assignee profile.
• 11 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Shanghai Zerun Biotechnology. Not investment advice.

• Peer + 0 momentum

  Trevi Therapeutics

  TA overlap score 22.2

• Peer + 0 momentum

  Contineum Therapeutics

  TA overlap score 21.4

Recent activity

Latest pipeline, patent, and corporate events for Shanghai Zerun Biotechnology.

1. Jun 8, 2026 Clinical update

   LTI-03-2001 (RENEW) — Phase 2

2. Jun 8, 2026 Clinical update

   BRCA-P/ABCSG 50 — Phase 3

3. Jun 8, 2026 Clinical update

   EASYlight-NEK — Approved

4. Jun 8, 2026 Clinical update

   ABCSG 45 — Phase 2

5. Jun 8, 2026 Clinical update

   TAMOXIFEN for Breast cancer — Phase 3

View all clinical trial activity →

• What is Shanghai Zerun Biotechnology?

  Shanghai Zerun Biotechnology is a pharma organization headquartered in Shanghai, CN. Primary therapeutic focus areas include Idiopathic Pulmonary Fibrosis, Prevention of breast cancer in women with a BRCA1 germline mutation, endocrine-responsive HER2-negative early breast cancer,

• Is Shanghai Zerun Biotechnology publicly traded?

  Shanghai Zerun Biotechnology appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Shanghai Zerun Biotechnology develop or market?

  We link 33 drug profile(s) where Shanghai Zerun Biotechnology is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/rein-therapeutics#company-drugs.

• What are the latest developments for Shanghai Zerun Biotechnology?

  In the last 12 months our linked public records show 11 trial program update(s) and 1 US patent grant(s) tied to this profile.

• What therapeutic areas does Shanghai Zerun Biotechnology focus on?

  Shanghai Zerun Biotechnology focuses on Idiopathic Pulmonary Fibrosis, Prevention of breast cancer in women with a BRCA1 germline mutation, endocrine-responsive HER2-negative early breast cancer based on our analysis of their pipeline programs and drug development activities.